Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.

IF 2.6 4区医学 Q2 UROLOGY & NEPHROLOGY Therapeutic Advances in Urology Pub Date : 2024-11-08 eCollection Date: 2024-01-01 DOI:10.1177/17562872241293779

Patrick Campbell, Georges Gebrael, Arshit Narang, Chadi Hage Chehade, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Nicolas Sayegh, Nishita Tripathi, Clara Tandar, Emre Dal, Haoran Li, Umang Swami, Neeraj Agarwal, Benjamin L Maughan

{"title":"Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.","authors":"Patrick Campbell, Georges Gebrael, Arshit Narang, Chadi Hage Chehade, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Nicolas Sayegh, Nishita Tripathi, Clara Tandar, Emre Dal, Haoran Li, Umang Swami, Neeraj Agarwal, Benjamin L Maughan","doi":"10.1177/17562872241293779","DOIUrl":null,"url":null,"abstract":"Background and objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied time to castration and testosterone recovery in real-world patients with aPC undergoing iADT with relugolix.Methods and design: Eligibility criteria for this retrospective study were histologically confirmed through the diagnosis of aPC and initiation of iADT with relugolix. Primary endpoints were time to castrate level of testosterone after relugolix initiation and time to recovery to noncastrate levels after relugolix discontinuation.Results: Overall, 25 patients with aPC were treated with iADT and with relugolix. Median time to serum testosterone <50 ng/dL was 1.13 months [range 0.67-2.5 months]. The median time to recovery >50 ng/dL was 1.4 months [range 0.83-6.57 months] from holding treatment with relugolix.Conclusion: iADT with relugolix is associated with a rapid time to testosterone suppression and recovery. These results may guide patients' counseling and monitoring of serum testosterone and PSA levels in patients wishing to pursue iADT for aPC.","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"16 ","pages":"17562872241293779"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549705/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872241293779","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied time to castration and testosterone recovery in real-world patients with aPC undergoing iADT with relugolix.

Methods and design: Eligibility criteria for this retrospective study were histologically confirmed through the diagnosis of aPC and initiation of iADT with relugolix. Primary endpoints were time to castrate level of testosterone after relugolix initiation and time to recovery to noncastrate levels after relugolix discontinuation.

Results: Overall, 25 patients with aPC were treated with iADT and with relugolix. Median time to serum testosterone <50 ng/dL was 1.13 months [range 0.67-2.5 months]. The median time to recovery >50 ng/dL was 1.4 months [range 0.83-6.57 months] from holding treatment with relugolix.

Conclusion: iADT with relugolix is associated with a rapid time to testosterone suppression and recovery. These results may guide patients' counseling and monitoring of serum testosterone and PSA levels in patients wishing to pursue iADT for aPC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用瑞格列奈进行间歇性雄激素剥夺治疗的晚期前列腺癌患者的睾酮抑制和恢复情况。

背景和目的：与持续性 ADT 相比，间歇性雄激素剥夺疗法（iADT）可明显改善晚期前列腺癌（aPC）患者的生活质量。在此，我们研究了现实世界中使用瑞格列奈进行 iADT 的前列腺癌患者的阉割时间和睾酮恢复情况：这项回顾性研究的资格标准是经组织学确诊为 aPC 并开始使用瑞格列奈进行 iADT。主要终点是开始使用瑞格列士后睾酮达到阉割水平的时间，以及停用瑞格列士后睾酮恢复到非阉割水平的时间：共有 25 名 aPC 患者接受了 iADT 和瑞格列奈治疗。从开始使用瑞格列奈治疗到血清睾酮达到 50 ng/dL 的中位时间为 1.4 个月[范围为 0.83-6.57 个月]。这些结果可为患者提供指导，并对希望采用 iADT 治疗 aPC 的患者的血清睾酮和 PSA 水平进行监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Advances in Urology Medicine-Urology

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.